Synaptic proteins in the postmortem anterior cingulate cortex in schizophrenia: Relationship to treatment and treatment response

Neuropsychopharmacology

Volumn 39, Issue 9, 2014, Pages 2095-2103

  Barksdale, K A ^a   Lahti, A C ^a   Roberts, Rosalinda C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CALCINEURIN; CALCIUM; GLUTAMIC ACID; MITOFUSIN 1; MITOFUSIN 2; NEUROLEPTIC AGENT; SYNAPTOPHYSIN; VESICULAR GLUTAMATE TRANSPORTER 1; GUANOSINE TRIPHOSPHATASE; MFN2 PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SLC17A7 PROTEIN, HUMAN; SYP PROTEIN, HUMAN;

ADULT; ANTERIOR CINGULATE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SYNAPSE; SYNAPSE VESICLE; TREATMENT FAILURE; TREATMENT RESPONSE; WESTERN BLOTTING; CINGULATE GYRUS; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CALCINEURIN; FEMALE; GTP PHOSPHOHYDROLASES; GYRUS CINGULI; HUMANS; MALE; MITOCHONDRIAL PROTEINS; SCHIZOPHRENIA; SYNAPTOPHYSIN; TREATMENT OUTCOME; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84904472555     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.57     Document Type: Review

References (50)

1. Altamura AC, Bassetti R, Cattaneo E, Vismara S (2005). Some biological correlates of drug resistance in schizophrenia: a multidimensional approach. World J Biol Psychiatry 6(Suppl 2): 23-30.
2. Anglin RE, Mazurek MF, Tarnopolsky MA, Rosebush PI (2012). The mitochondrial genome and psychiatric illness. Am J Med Genet B Neuropsychiatr Genet 159B: 749-759.
3. Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J et al (2003). Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 278: 17190-17197.
4. Baumgärtel K, Mansuy IM (2012). Neural functions of calcineurin in synaptic plasticity and memory. Learn Mem 19: 375-384.
5. Bellocchio EE, Reimer RJ, Fremeau RT Jr, Edwards RH (2000). Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 289: 957-960.
6. Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR (1996). Comparative evaluation of synaptophysinbased methods for quantification of synapses. J Neurocytol 12: 821-828.
7. Clayton EL, Anggono V, Smillie KJ, Chau N, Robinson PJ, Cousin MA (2009). The phospho-dependent dynamin-syndapin interaction triggers activity-dependent bulk endocytosis of synaptic vesicles. J Neurosci 29: 7706-7717.
8. Conley RR, Kelly DL (2001). Management of treatment resistance in schizophrenia. Biol Psychiatry 50: 898-911.
9. Daly C, Sugimori M, Moreira JE, Ziff EB, Llinás R (2000). Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc Natl Acad Sci 97: 6120-6125.
10. Eastwood SL, Harrison PJ (2001). Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 55: 569-578.
11. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK et al (2012). Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37: 2515-2521.
12. Fornito A, Yücel M, Dean B, Wood SJ, Pantelis C (2009). Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull 35: 973-993.
13. Fremeau RT Jr, Voglmaier S, Seal RP, Edwards RH (2004). VGLUTs define subsets of excitatory neurons and suggest novel roles for glutamate. Trends Neurosci 27: 98-103.
14. Garrity AG, Pearlson GD, McKiernan K, Lloyd D, Kiehl KA, Calhoun VD (2007). Aberrant 'default mode' functional connectivity in schizophrenia. Am J Psychiatry 164: 450-457.
15. Gemmell HG, Evans NT, Besson JA, Roeda D, Davidson J, Dodd MG et al (1990). Regional cerebral blood flow imaging: a quantitative comparison of technetium-99m-HMPAO SPECT with C15O2 PET. J Nucl Med 10: 1595-1600.
16. Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M et al (2003). Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 100: 8993-8998.
17. Greicius MD, Krasnow B, Reiss AL, Menon V (2003). Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 100: 253-258.
18. Greengard P (2001). The neurobiology of dopamine signaling. Biosci Rep 21: 247-269.
19. Kane JM, Honigfeld G, Singer J, Meltzer H (1988). Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24: 62-67.
20. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M et al (2010). Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 67: 231-239.
21. Kozlovsky N, Scarr E, Dean B, Agam G (2006). Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. Schizophr Res 83: 173-177.
22. Kraguljac NV, Reid MA, White D, Jones R, den Hollander J, Lowman D et al (2012a). Neurometabolites in schizophrenia and bipolar disorder - a systematic review and metaanalysis. Psychiatry Res 203: 111-125.
23. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC (2012b). Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology 37: 2635-2642.
24. Kwon SE, Chapman ER (2011). Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron 70: 847-854.
25. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Carpenter WT, McMahon R (2006). Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology 31: 221-230.
26. Lahti AC, Weiler MA, Holcomb HH, Tamminga CA, Cropsey KL (2009). Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology 34: 2675-2690.
27. Legros F, Lombès A, Frachon P, Rojo M (2002). Mitochondrial fusion in human cells is efficient, requires the inner membrane potential, and is mediated by mitofusins. Mol Biol Cell 12: 4343-4354.
28. Lidow MS, Song ZM, Castner SA, Allen PB, Greengard P, Goldman- Rakic PS (2001). Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry 49: 1-12.
29. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M et al (2012). Impaired mitochondrial function in psychiatric disorders. Nat Rev Neurosci 13: 293-307.
30. McMahon HT, Bolshakov VY, Janz R, Hammer RE, Siegelbaum SA, Südhof TC (1996). Synaptophysin, a major synaptic vesicle protein, is not essential for neurotransmitter release. Proc Natl Acad Sci USA 93: 4760-4764.
31. Meltzer HY (1997). Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 14: 1-20 Review.
32. Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010). Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 30: 4232-4240.
33. Oni-Orisan A, Kristiansen LV, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol Psychiatry 63: 766-775.
34. Perez-Costas E, Melendez-Ferro M, Rice MW, Conley RR, Roberts RC (2012). Dopamine pathology in schizophrenia: analysis of total and phosphorylated tyrosine hydroxylase in the substantia nigra. Front Psychiatry 3: 31.
35. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS et al (2010). Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68: 625-633.
36. Roberts R, Roche J, Somerville S, Conley R (2012). Ultrastructural distinctions between treatment responders and non-responders in schizophrenia: postmortem studies of the striatum. In: L'Abate L (eds) Mental Illness/Book 2. InTech: Rijeka, Croatia, pp 261-286.
37. Rodríguez VM, Andrée RM, Castejón MJ, Zamora ML, Alvaro PC, Delgado JL et al (1997). Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res 76: 51-61.
38. Rushlow WJ, Seah YH, Belliveau DJ, Rajakumar N (2005). Changes in calcineurin expression induced in the rat brain by the administration of antipsychotics. J Neurochem 4: 587-596.
39. Selemon LD, Goldman-Rakic PS (1999). The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45: 17-25.
40. Sheitman BB, Lieberman JA (1998). The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 32: 143-150.
41. Sheng ZH, Cai Q (2012). Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nat Rev Neurosci 13: 77-93.
42. Staal WG, Hulshoff Pol HE, Schnack HG, van Haren NE, Seifert N, Kahn RS (2001). Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. Am J Psychiatry 158: 1140-1142.
43. Sun T, Wu XS, Xu J, McNeil BD, Pang ZP, Yang W et al (2010). The role of calcium/calmodulin-activated calcineurin in rapid and slow endocytosis at central synapses. J Neurosci 30: 11838-11847.
44. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
45. Todtenkopf MS, Vincent SL, Benes FM (2005). A cross-study metaanalysis and three-dimensional comparison of cell counting in the anterior cingulate cortex of schizophrenic and bipolar brain. Schizophr Res 73: 79-89.
46. Wada A, Kunii Y, Ikemoto K, Yang Q, Hino M, Matsumoto J et al (2012). Increased ratio of calcineurin immunoreactive neurons in the caudate nucleus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37: 8-14.
47. Wiedenmann B, Franke WW (1985). Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38 000 characteristic of presynaptic vesicles. Cell 41: 1017-1028.
48. Wilson NR, Kang J, Hueske EV, Leung T, Varoqui H, Murnick JG et al (2005). Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. J Neurosci 25: 6221-6234.
49. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S et al (2004). An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci USA 101: 7158-7163.
50. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T et al (2007). Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc Natl Acad Sci USA 104: 2815-2820.